Latest Breaking News On - Versant venture ridgeline discovery engine - Page 1 : comparemela.com
Press release content from Business Wire. The AP news staff was not involved in its creation.
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
March 12, 2021 GMT
BOSTON (BUSINESS WIRE) Mar 12, 2021
Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.
BostonMassachusettsUnited-statesCambridgeCambridgeshireUnited-kingdomSwitzerlandBlackrockUnited-kingdom-generalMonte-rosaMarkus-warmuthDan-budwick